CytomX Therapeutics, Inc.
NASDAQCytomX Therapeutics heads into its August 7 earnings report with a notable divergence: short sellers have been trimming positions for weeks, yet the short interest base remains one of the heaviest in small-cap biotech. The retreat in bearish positioning is the clearest story ahead of the print. Short interest has fallen roughly 7% over the past week and nearly 5% across two…
Snapshot as of 2 Sept 2026
CytomX Therapeutics heads into its August 7 earnings report with a notable divergence: short sellers have been trimming positions for weeks, yet the short interest base remains one of the heaviest in small-cap…
CytomX Therapeutics enters a pivotal week with a headline-grabbing Regeneron collaboration pulling in one direction and a 14% stock decline pulling hard in the other. CytomX announced an expansion of its strategic…
CytomX Therapeutics enters today's earnings print carrying its heaviest short position in months — a setup that sharpens the stakes around CX-2051 clinical progress considerably. Short sellers have made a decisive move…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CTMX — free to start on ORTEX.
Sign up for free →Open CTMX on ORTEX